Modifying Epigenetic Landscapes to Restore Immune Therapeutic Responses in Triple Negative Breast Cancer
Authors:
Open Access
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer defined by the absence of estrogen and progesterone receptors, as well as the lack of human epidermal growth factor 2 receptor overexpression. TNBC is associated with early onset, high metastatic potential, therapeutic resistance, and poor clinical outcomes exacerbated by the limited availability of effective targeted therapies. Advances in multi-omics profiling have further stratified TNBC into distinct molecular subtypes, each exhibiting unique genomic, epigenomic, and immune-related features that influence therapeutic responsiveness. This review explores the interplay between TNBC molecular heterogeneity, immune evasion mechanisms, and epigenetic regulation. TNBC demonstrates variable immunogenicity, with tumor-infiltrating lymphocytes serving as important prognostic and predictive biomarkers. However, immune escape commonly occurs through tumor microenvironment remodeling, T-cell exhaustion, cancer stem cell enrichment, and immune checkpoint pathways activation. Although immune checkpoint inhibitors have improved outcomes in selected patients, particularly in combination with chemotherapy, primary and acquired therapeutic resistance remain a significant challenge. Emerging evidence highlights the central role of epigenetic mechanisms in regulating immune-related gene expression and shaping the tumor immune microenvironment. Epigenetic silencing of antigen presentation machinery, interferon signaling pathways, and chemokine expression contributes to immune evasion and immunotherapy resistance. Importantly, pharmacological modulation of epigenetic regulators can restore immune recognition and induce “viral mimicry” through reactivation of endogenous retroelements, thereby enhancing antitumor immunity. Collectively, this review underscores the therapeutic potential of integrating epigenetic therapies with immunotherapy and chemotherapy to overcome immune resistance in TNBC. A deeper understanding of epigenetic-immune interactions may facilitate the development of more precise and effective treatment strategies tailored to TNBC molecular subtypes.Keywords
Funding Information
- Biotechnology and Biological Sciences Research Council (BB/T0083690/1)
This publication has 106 references indexed in Scilit:
- Immunotherapy in Triple-Negative Breast CancerOncology and Therapy, 2025
- CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancerBiomedicine & Pharmacotherapy, 2024
- Subverted macrophages in the triple-negative breast cancer ecosystemBiomedicine & Pharmacotherapy, 2023
- ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosisCellular and Molecular Life Sciences, 2022
- Augmentation of antitumor function of tumor‐infiltrating lymphocytes against triple‐negative breast cancer by PD‐1 blockadeCell Biology International, 2021
- A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patternsBreast Cancer Research and Treatment, 2020
- miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapyCancer Immunology, Immunotherapy, 2020
- MicroRNAs in regulation of triple-negative breast cancer progressionJournal of Cancer Research and Clinical Oncology, 2018
- The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)Breast Cancer, 2017